Erez Chimovits

Biography

Mr. Chimovits has served as a member of the Board of Directors of Novus Therapeutics, Inc. since the acquisition of Otic Pharma, Ltd. by Novus Therapeutics (formerly Tokai Pharmaceuticals, Inc.) in May 2017. Prior to the acquisition, Mr. Chimovits served as a member of the Board of Directors for Otic Pharma. Mr. Chimovits is a Senior Managing Director at OrbiMed. He has more than 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed, he was the Chief Executive Officer of NasVax (TASE: NSVX). NasVax acquired Protea and struck key agreements with GlaxoSmithKline and Novartis. Previously, Mr. Chimovits spent more than seven years with Compugen (Nasdaq: CGEN), as President, Compugen USA Inc. and Executive Vice President, Commercial Operations. While at Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including J&J, Novartis, Teva, Abbott, Medarex and others. Mr. Chimovits earned his M.B.A., M.Sc. in Microbiology and his B.Sc. from Tel Aviv University. 

Research Interest

Novus Therapeutics, Inc. operates as a pharmaceutical company. The Company provides acquisition, development, and commercialization of medicinal products for ear, nose, and throat disorders